Updated Jan. 6, 2012 at 1:33 p.m.

Premium Lock Charlotte-based Chelsea Therapeutics discounts stock price for $19.2M offering

Published: 2012-01-06 13:03:00
Updated: 2012-01-06 13:33:03

Chelsea Chelsea

Chelsea's lead drug candidate is Droxidopa, which will be marketed under the name Northera. The drug candidate is aimed at treating dizziness and fainting commonly experienced by patients with Parkinson's disease. Northera has completed phase 3 clinical trials and is currently under priority review by the U.S. Food and Drug Administration....

Read More
Read More

Copyright 2017 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders